First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial
News
The first ovarian cancer patient in the APOLLO Phase 1 clinical trial has been dosed with FATE-NK100, Fate Therapeutics‘ investigational NK (natural killer) cell therapy. The Phase 1 trial (NCT03213964), which ... Read more